AlphAIAlphAI — Financial news for AI agents
seekingalpha.com$HAE

Haemonetics gains after update on CSL supply deal (HAE:NYSE)

Haemonetics (HAE) rose ~14% premarket Thursday after CSL Limited (CSLLY) announced plans to use HAE's devices in its U.S. plasma centers, per a prior supply agreement.

Original reporting
seekingalpha.com
Published Oct 8, 2026, 11:20 AM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Oct 8, 2026, 11:23 AM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
AlphAI market briefMarket movers
Primary signal
$HAE
Bullish
high confidence
Mentioned
$HAE
Relevance
8/10
AlphAI data visualization · based on seekingalpha.com
Decision brief

The 30-second read

$HAEBullishHigh
01

Why it matters

The announcement triggered a 14% pre‑market surge, indicating strong market confidence in the partnership.

02

Market read

The deal provides a clear growth catalyst for Haemonetics, likely supporting short‑term upside.

03

What to watch

Potential regulatory approvals for the devices in the U.S. could affect execution.

Relevance 8/10Novelty 8/10Timing: pre‑market today

Background

Haemonetics announced a supply agreement with CSL Limited, a leading biopharma company, to place its plasma collection devices in CSL's U.S. centers.

Company-level read

Ticker impact

$HAEBullishHigh confidence
Context

Haemonetics shares jumped ~14% pre‑market after CSL Limited confirmed deployment of its devices in U.S. plasma collection centers.

Expected impact

upward pressure as the market prices in the new CSL deployment.

Evidence & confidence

A material supply agreement with a major partner and a double‑digit pre‑market move indicate fresh, actionable catalyst.

Market effects

Sector

Positive signal for medical device and plasma‑collection equipment sector.

Regional

U.S. biotech/medical device market may see modest uplift.

Global

Limited to companies with similar supply‑chain partnerships.

Counterpoint

What could challenge this read

If the deployment timeline slips, the rally could reverse.

Key entities

  • Company
    Haemonetics

    Medical device maker (ticker HAE).

  • Company
    CSL Limited

    Biopharma firm (ticker CSLLY) partnering with Haemonetics.

Read at source← All news

StoryHaemonetics secures CSL Plasma rollout of NexSys PCS devices across U.S. centers by end‑2027

Also covered by

6 outlets

Related articles

$HAEMedAI 8/10

Haemonetics Corp (HAE) (Q2 2027) Earnings Call Highlights: Raised Guidance and Expanded

Haemonetics Corp (HAE) reported Q2 2027 earnings, raising guidance but lowering operating margin expansion due to higher costs and investments. CEO Christopher Simon highlighted a multiyear growth opportunity with CSL, though margin contributions are expected in fiscal 2028. The company faces near-term pressures from elevated production and freight costs, with second-half margin expansion weighted toward Q4.

finance.yahoo.com
$HAEHighAI 8/10

Haemonetics Corporation Q2 2027 Earnings Call Summary

Haemonetics reported Q2 2027 plasma growth of 18%, driven by Persona PLUS adoption. CSL relationship expansion and FDA approval for PerQseal Elite were highlighted. Revenue guidance raised to 6-9%, but margin expansion lowered due to supply chain costs. Free cash flow conversion expected to exceed 80%.

finance.yahoo.com
$HAEMedAI 8/10

Haemonetics (HAE) Q2 2027 Earnings Call Transcript

Haemonetics reported Q2 2027 earnings, highlighting 6% organic growth in MedSurg and 14% in Apheresis. Key drivers include TEG 6s disposables, VASCADE products, and Persona PLUS adoption. The company raised its fiscal 2027 revenue guidance to 6%-9% organic growth and 8%-11% reported growth, citing strong first-half performance and increased visibility into customer commitments.

finance.yahoo.com
$HAEMed

Mizuho raises Haemonetics stock price target on plasma strength

Mizuho raised its price target for Haemonetics (HAE) to $165 from $140, citing 18% organic plasma growth and improved guidance. The stock has gained 151% over the past year. HAE reported Q2 earnings of $1.35 per share, beating estimates, with revenue up 9.3% YoY. BTIG also raised its target to $142. Investors note margin guidance concerns and growth spending.

investing.com
$HAEHighAI 8/10

BTIG raises Haemonetics stock price target to $142 on earnings beat

BTIG raised its price target on Haemonetics (HAE) to $142 from $130, maintaining a Buy rating. HAE's Q2 2027 revenue was $357.8M, up 9.3% YoY, beating estimates. Adjusted EPS was $1.35, exceeding expectations. All segments performed well, with Apheresis revenue at $204.8M. Adjusted gross margin increased to 61.9%. HAE raised fiscal 2027 revenue guidance but reduced adjusted EBIT margin expansion outlook.

investing.com